推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 萬華化學(xué)3月16日晚發(fā)布2014年年報。報告期內(nèi)，公司實現(xiàn)銷售收入220.88億元，完成計劃的100%，同比增長9.14%;實現(xiàn)歸屬于母公司凈利潤24.19億元，同比減少16.33%;每股收益1.12元。公司擬向全體股東每10股派發(fā)3元現(xiàn)金紅利(含稅)。
公司表示，營業(yè)收入較上年同期增長9.14%，主要為本期主產(chǎn)品MDI的銷售數(shù)量增加，且石化產(chǎn)品及聚醚等其他產(chǎn)品銷售數(shù)量增加所致。公司主產(chǎn)品MDI的銷售數(shù)量較上年同期增長10.86%，石化產(chǎn)品及聚醚等其他產(chǎn)品銷售量合計較上年增長31.13%。不過，隨著經(jīng)濟增速放緩，2014年國內(nèi)MDI需求增速大幅減緩;而且，隨著萬華煙臺新裝置、拜爾上海和巴斯夫重慶裝置的投產(chǎn)，中國MDI產(chǎn)品將可能出現(xiàn)供過于求的局面，公司的經(jīng)營將面臨挑戰(zhàn)。
公司產(chǎn)品成本和銷售成本均較去年同比增長10%以上，財務(wù)費用較上年同期增加17,665萬元，增長68.55%。公司表示，主要原因是本期無匯兌收益，導(dǎo)致財務(wù)費用較上年同期增加8,953萬元;貸款的增加使利息支出較上年同期增加9,390萬元。寧波子公司不再符合高新技術(shù)企業(yè)條件后，企業(yè)所得稅稅率由15%調(diào)整為25%，使公司所得稅費用同比增加29,108萬元，增長44.11%。
